MedTrace Logo

A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

NCT00420823 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2015-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic medication in the treatment of First Episode Psychosis.Taurine may have an effect on cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month period.

Conditions

  • Psychotic Disorders

Interventions

DRUG

Taurine 4g

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Southern Health

    collaborator OTHER

  • Melbourne Health

    lead OTHER

Principal Investigators

  • Dr Colin P O'Donnell, MB,MRCPsych · ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31
Completion
2010-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420823 on ClinicalTrials.gov